 |
|
|
| |
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated
|
| |
| |
Reported by Jules Levin
EASL 2018 April 14 Paris France
Late Breaker oral
E Gane*1,2, A Liu3, MF Yuen4, C Schwabe2, Q Bo3, SK Das5, L Gao3, X Zhou3, Y Wang3, E Coakley6, Y Jin3 1. University of Auckland, 2. Auckland Clinical Studies, Auckland, New Zealand, 3. Roche Innovation Centre Shanghai, China, 4. Department of Medicine, The University of Hong Kong, Hong Kong, 5. Roche Products Ltd, Welwyn Garden City, United Kingdom, 6. Roche Innovation Centre New York, New York, United States 1
|
| |
|
|
|
|
|
